Synopsis
0
EU WC
0
KDMF
0
FDA Orange Book
0
Australia
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Evonik
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Faran Shimi Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Finar
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Bold Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Parenteral
Solubilizers
Topical
Fillers, Diluents & Binders
Emulsifying Agents
Film Formers & Plasticizers
Surfactant & Foaming Agents
API Stability Enhancers
Thickeners and Stabilizers
Controlled & Modified Release
Direct Compression
Co-Processed Excipients
Rheology Modifiers
Disintegrants & Superdisintegrants
Digital Content
NEWS #PharmaBuzz
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Dextran 40 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Dextran 40, including repackagers and relabelers. The FDA regulates Dextran 40 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Dextran 40 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Dextran 40 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Dextran 40 supplier is an individual or a company that provides Dextran 40 active pharmaceutical ingredient (API) or Dextran 40 finished formulations upon request. The Dextran 40 suppliers may include Dextran 40 API manufacturers, exporters, distributors and traders.
click here to find a list of Dextran 40 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Dextran 40 DMF (Drug Master File) is a document detailing the whole manufacturing process of Dextran 40 active pharmaceutical ingredient (API) in detail. Different forms of Dextran 40 DMFs exist exist since differing nations have different regulations, such as Dextran 40 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Dextran 40 DMF submitted to regulatory agencies in the US is known as a USDMF. Dextran 40 USDMF includes data on Dextran 40's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Dextran 40 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Dextran 40 suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Dextran 40 Drug Master File in Japan (Dextran 40 JDMF) empowers Dextran 40 API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Dextran 40 JDMF during the approval evaluation for pharmaceutical products. At the time of Dextran 40 JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Dextran 40 suppliers with JDMF on PharmaCompass.
A Dextran 40 CEP of the European Pharmacopoeia monograph is often referred to as a Dextran 40 Certificate of Suitability (COS). The purpose of a Dextran 40 CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Dextran 40 EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Dextran 40 to their clients by showing that a Dextran 40 CEP has been issued for it. The manufacturer submits a Dextran 40 CEP (COS) as part of the market authorization procedure, and it takes on the role of a Dextran 40 CEP holder for the record. Additionally, the data presented in the Dextran 40 CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Dextran 40 DMF.
A Dextran 40 CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Dextran 40 CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Dextran 40 suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Dextran 40 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Dextran 40 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Dextran 40 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Dextran 40 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Dextran 40 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Dextran 40 suppliers with NDC on PharmaCompass.
Dextran 40 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Dextran 40 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Dextran 40 GMP manufacturer or Dextran 40 GMP API supplier for your needs.
A Dextran 40 CoA (Certificate of Analysis) is a formal document that attests to Dextran 40's compliance with Dextran 40 specifications and serves as a tool for batch-level quality control.
Dextran 40 CoA mostly includes findings from lab analyses of a specific batch. For each Dextran 40 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Dextran 40 may be tested according to a variety of international standards, such as European Pharmacopoeia (Dextran 40 EP), Dextran 40 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Dextran 40 USP).
LOOKING FOR A SUPPLIER?
